One to one interventions to reduce sexually transmitted infections and under the age of 18 conceptions: A systematic review of the economic evaluations

Sexually Transmitted Infections

Volumn 83, Issue 6, 2007, Pages 441-447

  Barham, L ^a   Lewis, D ^a   Latimer, N ^b  

^a NERA ECONOMIC CONSULTING   (United States)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADOLESCENT PREGNANCY; CHLAMYDIA; CONTRACEPTION; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; ECONOMIC EVALUATION; GONORRHEA; HERPES; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY ADJUSTED LIFE YEAR; REINFECTION; REVIEW; SCREENING; SEXUALLY TRANSMITTED DISEASE; SYPHILIS; SYSTEMATIC REVIEW; UNPLANNED PREGNANCY; UNWANTED PREGNANCY;

ADOLESCENT; ADOLESCENT HEALTH SERVICES; AUSTRALIA; BENCHMARKING; CANADA; COST-BENEFIT ANALYSIS; COUNSELING; DATABASES, FACTUAL; EUROPE; FEMALE; GREAT BRITAIN; HUMANS; PREGNANCY; PREGNANCY IN ADOLESCENCE; QUALITY-ADJUSTED LIFE YEARS; SEXUALLY TRANSMITTED DISEASES; UNITED STATES;

EID: 35748983796     PISSN: 13684973     EISSN: None     Source Type: Journal    
DOI: 10.1136/sti.2007.025361     Document Type: Review

References (66)

1. http://www.hpa.org.uk/infections/topics_az/hiv_and_sti/sti-chlamydia/ general.htm (accessed 1 August 2007).
2. Lewis D, Barham L, Latimer N. Rapid Economic Review of Interventions (Including Screening) to Reduce the Transmission of Chlamydia and other Sexually Transmitted Infections and to Reduce the Rate of Under Eighteen Conceptions, Especially Among Vulnerable and At Risk Groups, for National Institute for Health and Clinical Excellence, 2006. http://www.nice.org.uk/ download.aspx?o=298584 (accessed 1 August 2007).
3. NICE The Guidelines Manual: Appendix G: Methodology Checklist: Economic Evaluations 2006 http://www.nice.org.uk/page.aspx7o=429865.
4. Adams EJ, LaMontagne DS, Johnston AR, et al. Modelling the healthcare costs of an opportunistic chlamydia screening programme. Sex Transm Infect 2004;80:363-370.
5. Blake DR. Cost-effectiveness analysis of screening adolescent males for chlamydia on admission to detention. Sex Transm Dis 2004;31:85-95.
6. Buhaug H. Should asymptomatic patients be tested for Chlamydia trachomatis in general practice? Br J Gen Practice 1990;40:142-5.
7. Cohen D. A school-based chlamydia control program using DNA amplification technology. Pediatrics 1998;101.
8. Dryden. Detection of chlamydia trachomatis in general practice urine samples. Br J Gen Practice 1994;33:114-17.
9. Gene M. A cost-effectiveness analysis of screening and treatment for Chlamydia trachomatis infection in asymptomatic women. Annals of Internal Medicine 1996;124:1-7.
10. Gift TL. A cost-effectiveness evaluation of testing and treatment of Chlamydia trachomatis infection among asymptomatic women infected with Neisseria gonorrhoeae. Sex Transm Dis 2002;29:542-51.
11. Gift TL, Malotte CK, Ledsky R, et al. A cost-effectiveness analysis of interventions to increase repeat testing in patients treated for gonorrhea or chlamydia at public sexually transmitted disease clinics. Sex Transm Dis 2005;32(9):542-9.
12. Ginocchio RHS, Veenstra DL, Connell FA, et al. The clinical and economic consequences of screening young men for genital chlamydial infection. Sex Transm Dis 2003;30:99-106.
13. Howell MR, Kassler WJ, Haddix A. Partner notification to prevent pelvic inflammatory disease in women: cost-effectiveness of two strategies. Sex Transm Dis 1997;24:287-92.
14. Howell MR, Quinn TC, Brathwaite W, et al. Screening women for chlamydia trachomatis in family planning clinics: the cost-effectiveness of DNA amplification assays. Sex Transm Dis 1998;25:108-17.
15. Howell MR, Gaydos JC, McKee KT Jr, et al. Control of Chlamydia trachomatis infections in female army recruits: cost-effective screening and treatment in training cohorts to prevent pelvic inflammatory disease. Sex Transm Dis 1999;26:519-26.
16. Hu D, Hook EW, et al. Screening for Chlamydia trachomatis in women 15 to 29 years of age: a cost-effectiveness analysis. Annals of Internal Medicine 2004;141:501-13.
17. Humphreys JT, Henneberry JF, Rickard RS, et al. Cost-benefit analysis of selective screening criteria for chlamydia-trachomatis infection in women attending Colorado family-planning clinics. Sex Transm Dis 1992;19:47-53.
18. Kraut-Becher JR, Gift TL, Haddix AC, et al. Cost-effectiveness of universal screening for chlamydia and gonorrhea in US jails. J Urban Health 2004;81:453-71.
19. Marrazzo JM, Celum CL, Hillis SD, et al. Performance and cost-effectiveness of selective screening criteria for chlamydia trachomatis infection in women: implications for a national chlamydia control strategy. Sex Transm Dis 1997;24:131-41.
20. Mehta SD, Bishai D, Howell R, et al. Cost-effectiveness of five strategies for gonorrhea and chlamydia control among female and male emergency department patients. Sex Transm Dis 2002;29:83-91.
21. Mrus JM, Biro FM, Huang B, et al. Evaluating adolescents in juvenile detention facilities for urogenital chlamydial infection û cost and effectiveness of alternative interventions. Arch Pediatr Adolesc Med 2003;157:696-702.
22. Norman JE, Wu O, Twaddle S, et al. An evaluation of economics and acceptability of screening for chlamydia trachomatis infection, in women attending antenatal, abortion, colposcopy and family planning clinics in Scotland. Obstet Gynecol 2004;111:1261-8.
23. Paavonen J, Puolakkainen M, Paukku M, et al. Cost-benefit analysis of first-void urine chlamydia trachomatis screening program. Obstet Gynecol 1998;92:292-8.
24. Peeling RW, Toye B, Jessamine P, et al. Noninvasive screening for genital chlamydial infections in asymptomatic men: Strategies and costs using a urine PCR assay. Can J Infect Dis 1998;9(5):281-6.
25. Poshna M, Weite R, van den Hoek A, et al. Cost-effectiveness of screening asymptomatic women for chlamydia trachomatis: The importance of reinfection and partner referral. Health Economics in Prevention and Care 2000;1:103-10.
26. Poshna MJ. Cost effectiveness of partner pharmacotherapy in screening women for asymptomatic infection with chlamydia trachomatis. Value in Health 2001;4:266-75.
27. Sellers JW, Pickard L, Gafni A, et al. Effectiveness and efficiency of selective vs universal screening for chlamydial infection in sexually active young women. Arch Intern Med 1992;152:1837-44.
28. Van Bergen JEAM, Postma MJ, Peerbooms PGH, et al. Effectiveness and cost-effectiveness of a pharmacy-based screening programme for Chlamydia trachomatis in a high-risk health centre population in amsterdam using mailed home-collected urine samples, Int J STD AIDS 2004;15:797-802.
29. van VI, Postma MJ, Morre SA, et al. Cost effectiveness analysis of a population based screening programme for asymptomatic Chlamydia trachomatis infections in women by means of home obtained urine specimens. Sex Transm Infect 2001;77:276-82.
30. Ward B, Rodger AL, Jackson TJ. Modelling the impact of opportunistic screening on the sequelae and public healthcare costs of infection with chlamydia trachomatis in Australian women. Public Health 2006;120:42-9.
31. Weite R, Kretzschmar M, Leidl R, et al. Cost-effectiveness of screening programs for Chlamydia trachomatis: a population-based dynamic approach. Sex Transm Dis 2000;27:518-29.
32. Weite R, Postma M, Leidl R, et al. Costs and effects of chlamydial screening: dynamic versus static modeling. Sex Transm Dis 2005;32:474-83.
33. Bramley D, Graves N, Walker D. The cost effectiveness of universal antenatal screening for hiv in new Zealand. AIDS 2003;17:741-8.
34. Brandeau ML, Owens DK, Sox CH, et al. Screening women of childbearing age for human immunodeficiency virus. A cost benefit analysis. Arch InternMed 1992;152:2229-37.
35. Bos JM, Johnan Fennema JSA, Postma MJ. Cost-effectiveness of HIV screening of patients. AIDS 2001;15:2031-6.
36. Gibb DM, Ades AE, Gupta R, et al. Costs and benefits to the mother of antenatal HIV testing: estimates from simulation modelling. AIDS 1999;13:1569-76.
37. Neumann KS, Marx R, Lawrence SJ, et al. Cost-effectiveness of prevention referrals for high-risk HIV-negatives in San Francisco. AIDS Care 2001;13:637-42.
38. Holtgrave DR, Valdiserri, et al. Human Immunodeficiency Virus counseling, testing, referral and partner notification services: a cost-benefit analysis. Arch Intern Med 1993;153:1225-30.
39. Hughes D, Morris S. The cost-effectiveness of condoms in the prevention of HIV infection in England and Wales: should condoms be available on prescription. J Health Serv Res Policy 1996;1:205-11.
40. La Croix SJ, Russo G. A cost-benefit analysis of voluntary routine HIV-antibody testing for hospital patients. Soc Sci Med 1996,42:1259-72.
41. Lurie P, Avins, et al. The cost-effectiveness of voluntary counseling and testing of hospital inpatients for HIV infection. JAMA 1994;272:1832-8.
42. Owens D, Nease R, Harris R. Cost-effectiveness of HIV screening in acute care settings. Arch Intern Med 1996;156:394-404.
43. Paltiel AD, Weinstein MC, Kimmel AD, et al. Expanded screening for HIV in the United States û an analysis of cost-effectiveness. The New England Journal of Medicine 2005;352:586-95.
44. Phillips KA, Fernyak S. The cost-effectiveness of expanded HIV counselling and testing in primary care settings: a first look. AIDS 2000;14:2159-69.
45. Pinkerton SD, Holtgrave DR, Bloom FR. Cost-effectiveness of post-exposure prophylaxis following sexual exposure to HIV. AIDS 1998;12:1067-78.
46. Sanders GD, Bayoumi AM, Sundaram V, et al. Cost-effectiveness of screening of HIV in the era of highly active antiretroviral therapy. N Engl J Med 2005;352:570-85.
47. Too G, Remafedi G. Economic evaluation of an HIV prevention intervention for gay and bisexual male adolescents. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:83-90.
48. Toomey KE, Peterman TA, Dicker LW, et al. Human immunodeficiency virus partner notification:cost and effectiveness data from an attempted randomized controlled trial. Sex Transm Dis 1998;25:310-16.
49. Varghese B, Peterman TA. Cost-effectiveness of counseling and testing and partner notification: a decision analysis. AIDS 1999;13(13):1745-51.
50. Varghese B, Peterman TA. Cost-effectiveness of HIV counseling and testing in US prisons. J Urban Health 2001;78:304-12.
51. Zowall H, Fraser RD, Gilmore N, et al. HIV antibody screening among immigrants: a cost-benefit analysis. Can Med Assoc J 1990;143:101-7.
52. Clark KL. Cost-effective syphilis screening in military recruit applicants. Military Medicine 1999;164:580-4.
53. Engelgau MM, Woernle CH, Rolfs RT, et al. Control of epidemic early syphilis: the results of an intervention campaign using social networks. Sex Transm Dis 1995;22:203-9.
54. Reynolds SL, Kapadia AS, Leonard L, et al. Examining the direct costs and effectiveness of syphilis detection by selective screening and partner notification. J Public Health Med 2001;23:339-45.
55. Silberstein GS. Effectiveness and cost-benefit of enhancement to a syphilis screening and treatment program at a county jail. Sex Transm Dis 2000;27:508-17.
56. Fisman DN, Hook EW, Goldie SJ. Estimating the costs and benefits of screening monogamous, heterosexual couples for unrecognised infection with herpes simplex virus Type 2. Sex Transm Infect 2003;79:45-52.
57. Bedimo AL. Condom distribution: a cost-utility analysis, Int J STD AIDS 2002;13:384-92.
58. Mordante KD, Gardner JS, Veenstra DL, et al. Modeling the cost and outcomes of pharmacist-prescribed emergency contraception. Am J Public Health 2001;91:1443-5.
59. Cohen DA. Comparing the cost-effectiveness of HIV prevention interventions. AIDS 2004;37:1404-14.
60. Henry-Suchet J, Sluzhinska A, Serfaty D. Chlamydia trachomatis screening in family planning centers: a review of cost/benefit evaluations in different countries. Eur J Contracept Reprod Health Care 1996;1:301-9.
61. Hollgrave DR. An overview of the effectiveness and efficacy of HIV prevention programmes. Public Health Reports 1995;110:134-46.
62. Holtgrave DR, Quails NL, Graham JD. Economic evaluation of HIV prevention programs. Annu Rev Public Health 1996;17:467-88.
63. Honey E, Augood C, Templeton A, et al. Cost effectiveness of screening for Chlamydia trachomatis: a review of published studies. Sex Transm Infect 2002,78:406-12.
64. Mangione SR, apos O, Leary J, et al. Health and cost-benefits of chlamydia screening in young women. Sex Transm Dis 1999;26:309-16.
65. Roberts TE, et al (2005) Screening for Chlamydia trachomatis: a systematic review of the economic evaluations and modelling. Sex Transm Inf 2006;83:193-200.
66. Weite R, Jager H, Postma MJ. Cost-effectiveness of screening for genital Chlamydia trachomatis. Expert Review of Pharmacoeconomics & Outcomes Research 2001;1:145-56.